UBS Initiates Vylor at Buy With $89 Price Target

UBS initiated coverage of Vylor with a 'Buy' rating and a $89 price target. The stock has risen 8.76% year-to-date and 9.13% over 5 days. Goldman Sachs also initiated coverage with a 'Buy' rating and $87 target.

Original reporting
Published Oct 12, 2026, 11:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 12:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$VYLR
Relevance
6/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Med
01

Why it matters

The new coverage may generate short-term interest and price movement, but lacks substantive financial data.

02

Market read

Analyst initiation provides fresh information that could influence trading decisions for Vylor.

03

What to watch

No disclosed financial metrics or earnings guidance accompany the rating.

Relevance 6/10Novelty 7/10Timing: pre-market today

Background

UBS initiated coverage on Vylor with a Buy rating and a $89 price target, following a prior Goldman Sachs initiation at $87.

Market effects

Analyst coverage may affect the sector's valuation perception.

Limited to markets where the company trades.

Low global impact.

Counterpoint

The rating could be premature if the company's fundamentals are weak.

Key entities

  • UBS

    Initiated coverage on Vylor with a Buy rating.

  • Goldman Sachs

    Previously initiated coverage on Vylor at a $87 target.

Related articles

$VYLRMed

Vylor Inc Faces Legal Challenges After Recent Spin-Off

Vylor Inc (VYLR) faces legal challenges from 16 U.S. plaintiffs over its recent spin-off from Corteva. A court issued a temporary restraining order on Oct 9, 2026, limiting asset disposal and prohibiting dividends and buybacks, though it was stayed the next day. The separation is complete, but litigation continues, affecting capital allocation. VYLR has a $89.00 price target and Buy rating. The company's market cap is $50.64B.

$VYLRMed

Vylor Inc. (VYLR): 15 states and one sovereign commenced litigation in the United States District Court for the Southern District of Indiana challenging the separation of…

Vylor Inc. (VYLR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 1, 2026, 15 states and one sovereign commenced litigation in the United States District Court for the Southern District of Indiana (the “District Court”) challenging the separation of Corteva, Inc. (“Corteva”) and Vylor Inc. (the “Company” or “V

$VYLRMed

Vylor Inc. (VYLR) Stock Forecasts

Morningstar initiates coverage of Vylor Inc. (VYLR) with a $80 fair value estimate, rating the shares as undervalued. The company, spun off from Corteva in 2026, specializes in genetically modified seeds and crop genetics. Analyst Seth Goldstein highlights Vylor's leadership in advanced germplasm and traits that enhance crop yields.

$VYLRMedAI 8/10

What Does Vylor (VYLR) Joining Major Indices Mean For Investors?

Vylor (VYLR) has been added to major indices like the S&P 500 and FTSE All-World after its spin-off from Corteva (CTVA). The company amended its governance documents and issued $1.44b in senior unsecured bonds. Vylor's $48.6b market value means index changes affect institutional exposure. Investors should monitor earnings and capital allocation in upcoming reports.

$VYLRHighAI 9/10

Vylor completes major acquisition and refinancing transactions

Vylor Inc. (VYLR) completed an acquisition and refinancing on October 1, 2026. It issued 667.3 million new shares to EIDP, Inc., a Corteva subsidiary, in exchange for Pioneer Hi-Bred International, Inc. and $761 million in cash. Vylor also drew $3.078 billion to repay borrowings, simplifying its debt structure. Analysts rate VYLR stock as Buy with a $82.00 target.